CN104043058A - 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 - Google Patents
一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN104043058A CN104043058A CN201410311332.1A CN201410311332A CN104043058A CN 104043058 A CN104043058 A CN 104043058A CN 201410311332 A CN201410311332 A CN 201410311332A CN 104043058 A CN104043058 A CN 104043058A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- rhizoma
- radix
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000007812 deficiency Effects 0.000 title claims abstract description 51
- 210000003734 kidney Anatomy 0.000 title abstract description 69
- 206010050296 Intervertebral disc protrusion Diseases 0.000 title abstract 3
- 210000000582 semen Anatomy 0.000 claims abstract description 121
- 238000011282 treatment Methods 0.000 claims abstract description 91
- 241000222336 Ganoderma Species 0.000 claims abstract description 35
- 241000660877 Coridius Species 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 32
- 244000173297 Medicago polymorpha Species 0.000 claims abstract description 31
- 235000017823 Medicago polymorpha Nutrition 0.000 claims abstract description 31
- 241000218176 Corydalis Species 0.000 claims abstract description 29
- 241000005787 Cistanche Species 0.000 claims abstract description 25
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 173
- 239000003814 drug Substances 0.000 claims description 107
- 241001453798 Nephrolepis Species 0.000 claims description 52
- 239000013521 mastic Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 33
- 241000237636 Pheretima Species 0.000 claims description 30
- 208000012287 Prolapse Diseases 0.000 claims description 30
- 241000545442 Radix Species 0.000 claims description 30
- 241000229143 Hippophae Species 0.000 claims description 28
- 235000003935 Hippophae Nutrition 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 25
- 238000010992 reflux Methods 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- 244000064622 Physalis edulis Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 244000025254 Cannabis sativa Species 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 241000220433 Albizia Species 0.000 claims description 15
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 15
- 241000726094 Aristolochia Species 0.000 claims description 15
- 241000220451 Canavalia Species 0.000 claims description 15
- 235000005903 Dioscorea Nutrition 0.000 claims description 15
- 241000234273 Dioscorea Species 0.000 claims description 15
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 15
- 244000184734 Pyrus japonica Species 0.000 claims description 15
- 241000792914 Valeriana Species 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 15
- 235000017468 valeriana Nutrition 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 229960004793 sucrose Drugs 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 235000013372 meat Nutrition 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000003113 dilution method Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 abstract description 61
- 230000036407 pain Effects 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 58
- 230000008901 benefit Effects 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 235000010518 Canavalia gladiata Nutrition 0.000 abstract description 2
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract description 2
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 abstract 1
- 241001355283 Cayratia Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 240000003173 Drymaria cordata Species 0.000 abstract 1
- 240000001723 Entada phaseoloides Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000096284 Gynochthodes officinalis Species 0.000 abstract 1
- 240000007049 Juglans regia Species 0.000 abstract 1
- 235000009496 Juglans regia Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000146029 Lindera aggregata Species 0.000 abstract 1
- 241000612166 Lysimachia Species 0.000 abstract 1
- 235000009387 Medicago orbicularis Nutrition 0.000 abstract 1
- 241001453796 Nephrolepis cordifolia Species 0.000 abstract 1
- 240000005992 Physalis angulata Species 0.000 abstract 1
- 235000015857 Physalis angulata Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241001530209 Swertia Species 0.000 abstract 1
- 241001232424 Symphyotrichum subulatum Species 0.000 abstract 1
- 241000301400 Trogopterus Species 0.000 abstract 1
- 244000126014 Valeriana officinalis Species 0.000 abstract 1
- 235000013832 Valeriana officinalis Nutrition 0.000 abstract 1
- 241000212749 Zesius chrysomallus Species 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 244000237330 gutta percha tree Species 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 235000016788 valerian Nutrition 0.000 abstract 1
- 235000020234 walnut Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 60
- 210000004369 blood Anatomy 0.000 description 56
- 210000001624 hip Anatomy 0.000 description 39
- 208000008035 Back Pain Diseases 0.000 description 30
- 208000008930 Low Back Pain Diseases 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 210000003205 muscle Anatomy 0.000 description 26
- 201000010099 disease Diseases 0.000 description 25
- 230000001737 promoting effect Effects 0.000 description 24
- 235000009508 confectionery Nutrition 0.000 description 21
- 210000000988 bone and bone Anatomy 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 19
- 239000007789 gas Substances 0.000 description 17
- 206010007247 Carbuncle Diseases 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 206010011224 Cough Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000027939 micturition Effects 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 210000000629 knee joint Anatomy 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 206010000087 Abdominal pain upper Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 208000004880 Polyuria Diseases 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 230000035619 diuresis Effects 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 201000001881 impotence Diseases 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 231100000614 poison Toxicity 0.000 description 11
- 238000005728 strengthening Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000003141 lower extremity Anatomy 0.000 description 9
- 230000008736 traumatic injury Effects 0.000 description 8
- 206010002383 Angina Pectoris Diseases 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 208000001848 dysentery Diseases 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000002398 materia medica Substances 0.000 description 7
- 230000003014 reinforcing effect Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 description 6
- 206010021118 Hypotonia Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 6
- 208000031975 Yang Deficiency Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 208000017561 flaccidity Diseases 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000008967 Enuresis Diseases 0.000 description 4
- 206010024453 Ligament sprain Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000010040 Sprains and Strains Diseases 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 206010044302 Tracheitis Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 206010036596 premature ejaculation Diseases 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 206010033425 Pain in extremity Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 235000019616 numbness Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 206010039722 scoliosis Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- QRMPRVXWPCLVNI-YYFQZIEXSA-N Curcumol Chemical compound C1C(=C)[C@@H]2CC[C@H](C)[C@@]22C[C@@H](C(C)C)[C@]1(O)O2 QRMPRVXWPCLVNI-YYFQZIEXSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 208000007623 Lordosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 201000010934 exostosis Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000006793 Artemisia stelleriana Nutrition 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 240000003049 Canavalia gladiata Species 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000124705 Endospermum chinense Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016173 Fall Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010019477 Hemivertebra Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010063410 Lumbarisation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000420100 Morinda lucida Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010064932 Sacralisation Diseases 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241000775848 Syringa oblata Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000003164 cauda equina Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000006413 coastal sagewort Nutrition 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004446 longitudinal ligament Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法,中药制剂中各种原料药为:苦蘵、木香、乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加、沙棘、鹿茸、淫羊藿、巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁、肾蕨、红直当药、韭菜子和黄芪 。本发明的有益效果是:本发明具有补肾益精,理气止痛的功效,主治肾虚型腰椎间盘突出,具有起效快、有效率高、疗效确切、治疗疗程短、无毒副作用,价格低等优势。
Description
技术领域
本发明涉及中药制剂技术领域,特别涉及一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法。
背景技术
腰椎间盘突(脱)出是骨科门诊最为多见的疾患之一,也是腰腿痛最为多见的原因。腰椎间盘位于两个椎体之间,是一个具有流体力学特性的结构,由髓核、纤维环和软骨板三部分构成,其中髓核为中央部分,纤维环为周围部分,包绕髓核,软骨板为上、下部分,直接与椎体骨组织相连,整个腰椎间盘的厚度为8mm~10mm。
腰椎(L)位于脊柱下部,具有运动、负荷和保护功能。其上接胸椎,下连骶椎,其负荷和稳定功能尤为重要。腰椎前部由椎体借助椎间盘和纵韧带连接而成;后部由椎弓、椎板、横突和棘突构成。其间借助关节、韧带和肌肉等连接。腰椎的前后结构间围成椎孔,各椎节依序列连成椎管,其间容纳脊髓下端、圆锥和马尾神经根。
腰椎间盘突出的发病机制:1.主要病因:腰椎间盘在脊柱的负荷与运动中承受强大的压应力。大约在20岁以后,椎间盘开始退变,并构成腰椎间盘突出症的基本病因。此外,腰椎间盘突出与下列因素有关:(1)外伤:外伤是椎间盘突出的重要因素,特别是儿童与青少年的发病,与之密切相关。在脊柱轻度负荷和快速旋转时,可引起纤维环的水平破裂,而压应力主要使软骨终板破裂。外伤只是引起椎间盘突出的诱因,原始病变在于无痛的髓核突入内层纤维环,而外伤使髓核进一步突出到外面有神经支配的外层纤维环,从而引起疼痛。(2)职业:职业与腰椎间盘突(脱)出的关系十分密切。(3)遗传因素:腰椎间盘突出有家族性发病的报道,在国内材料较少;此外,统计数字表明,印第安人、非洲黑种人和因纽特人的发病率较其他民族的发病率明显为低。(4)腰骶先天异常:腰骶段畸形可使发病率增高,包括腰椎骶化、骶椎腰化、半椎体畸形、小关节畸形和关节突不对称等。2.诱发因素:本病除上述各种主要原因,即椎间盘的退行性变所致外,各种诱发因素亦具有重要作用,例如,某些稍许增加腹压的因素即可使髓核突出。其原因主要是,在椎间盘退行性变的基础上,某种可诱发椎间隙压力突然升高的因素致使呈游离状态的髓核穿过已变性、薄化的纤维环进入椎管前方或穿过椎板侵入椎体边缘处。
中医理论认为腰椎间盘突出的病因病机由以下几个方面:1.外邪侵袭多由居处潮湿,或劳作汗出当风,衣裹冷湿,或冒雨着凉,或长夏之季,劳作于湿热交蒸之处,寒湿、湿热、暑热等六淫邪毒乘劳作之虚,侵袭腰府,造成腰部经脉受阻,气血不畅而发生腰痛。若寒邪为病,寒伤阳,主收引,腰府阳气既虚,络脉又壅遏拘急故生腰痛。若湿邪为病,湿性重着、粘滞、下趋,滞碍气机,可使腰府经气郁而不行,血络瘀而不畅,以致肌肉筋脉拘急而发腰痛。感受湿热之邪,热伤阴,湿伤阳,且湿热粘滞,壅遏经脉,气血郁而不行而腰痛。2.气滞血瘀腰部持续用力,劳作太过,或长期体位不正,或腰部用力不当,摒气闪挫,跌仆外伤,劳损腰府筋脉气血,或久病人络,气血运行不畅,均可使腰部气机壅滞,血络瘀阻而生腰痛。3.肾亏体虚先天禀赋不足,加之劳累太过,或久病体虚,或年老体衰,或房室不节,以致肾精亏损,无以濡养腰府筋脉而发生腰痛。历代医家都重视肾亏体虚是腰痛的重要病机。如《灵枢·五癃津液别》说:“虚,故腰背痛而胫酸。”《景岳全书·腰痛》也认为:“腰痛之虚证十居八九。”
分析腰椎间盘突出的病因,多为外受伤损,内有亏虚或感受风寒湿邪等,故辨其临床证候分为:1、寒湿腰痛症状:腰部冷痛重着,转侧不利,逐渐加重,每遇阴雨天或腰部感寒后加剧,痛处喜温,得热则减,苔白腻而润,脉沉紧或沉迟。2、湿热腰痛症状:腰髋弛痛,牵掣拘急,痛处伴有热感,每于夏季或腰部着热后痛剧,遇冷痛减,口渴不欲饮,尿色黄赤,或午后身热,微汗出,舌红苔黄腻,脉濡数或弦数。3、瘀血腰痛症状:痛处固定,或胀痛不适,或痛如锥刺,日轻夜重,或持续不解,活动不利,甚则不能转侧,痛处拒按,面晦唇暗,舌质隐青或有瘀斑,脉多弦涩或细数。病程迁延,常有外伤、劳损史。4、肾虚腰痛症状:腰痛以酸软为主,喜按喜揉,腿膝无力,遇劳则甚,卧则减轻,常反复发作。偏阳虚者,则少腹拘急,面色光白,手足不温,少气乏力,舌淡脉沉细;偏阴虚者,则心烦失眠,口燥咽干,面色潮红,手足心热,舌红少苔,脉弦细数。治法:偏阳虚者,宜温补肾阳;偏阴虚者,宜滋补肾阴。
目前治疗腰椎间盘突出的方法主要有非手术方法治疗和手术治疗,非手术治疗也称保守治疗,常用的方法有:牵引治疗,物理疗法如:短波、超短波疗法;间动电疗阖;超刺激电流疗法;手术治疗,药物治疗如:硫酸软骨素A;抗炎和止痛药物;局部封闭疗法;代替疗法等综合治疗。
但是西医治疗腰椎间盘突出药物治疗疗程较长,毒副作用较多,对肝、肾、胃损害较大,易产生耐药性,临床疗效不甚显著;手术治疗创伤性较大,风险较大,并且往往难以根治。
发明内容
本发明所要解决的技术问题在于,提供一种治疗肾虚型腰椎间盘突出的中药制剂及其制备,本发明具有补肾益精,理气止痛的功效,主治肾虚型腰椎间盘突出。本发明利用传统中医理论,讲究整体观,通过调节全身气血生成,补精益髓,调节血液循环,营养神经,可改善突出物与神经之间的关系,松弛腰背部肌肉,恢复腰椎的正常列线,消除渗出、水肿,缓解疼痛,改善纤维软骨,并且具有起效快、有效率高、疗效确切、治疗疗程、无毒副作用,价格低,给药方便,安全有效,病人易于接受等优势。
为了解决上述技术问题,本发明提供一种治疗肾虚型腰椎间盘突出的中药制剂,其中,包括以下原料药材:苦蘵、木香、乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加、沙棘、鹿茸、淫羊藿、巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁、肾蕨、红直当药、韭菜子和黄芪。
其中,所述中药制剂中各原料药材的重量份数比可以优选为:苦蘵12~30份、木香15~35份、乌药10~25份、南苜蓿17~30份、天仙藤10~26份、九香虫15~30份、瑞连草14~28份、刀豆12~22份、川芎15~27份、姜黄15~25份、五灵脂18~30份、夏天无17~26份、匐地龙16~27份、丹参18~30份、牛膝15~25份、缬草16~25份、合欢皮10~20份、繁缕15~26份、灵芝12~25份、山药11~26份、乌蔹莓15~25份、甘草15~28份、刺五加15~30份、沙棘12~27份、鹿茸15~27份、淫羊藿15~30份、巴戟天10~20份、杜仲12~25份、仙茅15~25份、肉苁蓉15~30份、菟丝子10~28份、核桃仁16~30份、肾蕨17~35份、红直当药18~27份、韭菜子10~20份和黄芪15~30份。
其中,所述中药制剂中各原料药材的重量份数比还可以优选为:苦蘵15~26份、木香18~30份、乌药15~22份、南苜蓿19~27份、天仙藤15~25份、九香虫17~28份、瑞连草15~25份、刀豆15~20份、川芎17~25份、姜黄18~22份、五灵脂18~25份、夏天无19~25份、匐地龙17~25份、丹参19~25份、牛膝17~22份、缬草17~20份、合欢皮12~20份、繁缕17~25份、灵芝15~22份、山药12~25份、乌蔹莓17~22份、甘草16~25份、刺五加17~25份、沙棘15~25份、鹿茸17~25份、淫羊藿15~25份、巴戟天12~20份、杜仲15~28份、仙茅17~22份、肉苁蓉17~25份、菟丝子12~25份、核桃仁18~28份、肾蕨19~30份、红直当药19~25份、韭菜子12~20份和黄芪15~28份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵22份、木香20份、乌药18份、南苜蓿25份、天仙藤21份、九香虫23份、瑞连草17份、刀豆19份、川芎20份、姜黄20份、五灵脂23份、夏天无22份、匐地龙19份、丹参22份、牛膝19份、缬草18份、合欢皮18份、繁缕23份、灵芝20份、山药18份、乌蔹莓19份、甘草23份、刺五加21份、沙棘22份、鹿茸23份、淫羊藿17份、巴戟天15份、杜仲25份、仙茅19份、肉苁22份、菟丝子18份、核桃24份、肾蕨23份、红直当药22份、韭菜子17份和黄芪25份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵25份、木香19份、乌药22份、南苜蓿23份、天仙藤25份、九香虫25份、瑞连草17份、刀豆16份、川芎22份、姜黄20份、五灵脂21份、夏天23份、匐地龙24份、丹参22份、牛膝19份、缬草19份、合欢皮15份、繁缕22份、灵芝21份、山药21份、乌蔹莓19份、甘草20份、刺五加22份、沙棘23份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉21份、菟丝子13份、核桃仁25份、肾蕨20份、红直当药25份、韭菜子15份和黄芪18份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵17份、木香24份、乌药22份、南苜蓿23份、天仙藤25份、九香虫28份、瑞连草22份、刀豆19份、川芎23份、姜黄20份、五灵脂23份、夏天无21份、匐地龙24份、丹参22份、牛膝18份、缬草19份、合欢皮15份、繁缕22份、灵芝20份、山药24份、乌蔹莓21份、甘草18份、刺五加24份、沙棘18份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉24份、菟丝子19份、核桃仁24份、肾蕨25份、红直当药20份、韭菜子15份和黄芪22份。
其中,当所述中药的剂型为片剂时,其制备方法包括以下步骤:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为85%~95%的乙醇,加热回流4~6小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2~4倍的醇浓度为90%~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~3小时,粉碎,过筛,获得400目~500目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1~0.2倍的微晶纤维素、0.15~0.3倍乳糖、0.2~0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.025~0.04倍硬脂酸镁,整粒,压片,制成。
其中,当所述中药的剂型为口服液时,其制备方法包括以下步骤:
第一步,将南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加和沙棘混合,加相对于混合物6~8倍量醇浓度为90%~95%的乙醇回流提取2~3次,每次3~5小时,分别过滤,各次滤液合并,回收乙醇,浓缩至70℃相对密度为1.37~1.39的膏体,备用;
第二步,将剩余原料药材按比例混合,加相对于混合物5~7倍量水,煮沸4~6小时,过滤,浓缩至70℃相对密度为1.32~1.36的膏体;
第三步,将第一步、第二步获得的所述膏体混合,70℃~80℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为65%~80%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为24~48小时,冷藏温度为3℃~6℃;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.2~0.35;所述脱醇膏体与所述活性炭的重量比为1∶0.003~0.005;所述加热处理的时间为70~90分钟,温度为150℃~180℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
其中,当所述中药的剂型为贴片剂时,其制备方法包括以下步骤,
第一步,将乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无和匐地龙按所述比例混合,用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流2~3小时后提取,过滤,得第一过滤液;将滤渣再次用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流1~2小时后提取,过滤,得第二过滤液;合并第一过滤液和第二过滤液,减压回收乙醇并浓缩至药液浓度为0.6~0.8g生药/mL,经体积为5L的大孔吸附树脂柱洗脱,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为80%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁和肾蕨按所述比例混合,加相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇加热回流提取2~3次,提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~80℃的条件下减压浓缩至60℃时相对密度为1.20~1.24的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~3倍的水溶解,加热煎煮3~5小时,过滤;将滤渣再次用相对于获得的混合物质量的1~2倍的水溶解,加热煎煮1~2小时,过滤;合并两次的过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,加入相对于所述中药各原料药材质量之和的1~2倍的橡胶、1~2倍的松香,混合,制成涂料,进行涂膏,切断,盖衬,切片,即获得所述贴片剂。
本发明的有益效果是:本发明具有补肾益精,理气止痛的功效,主治肾虚型腰椎间盘突出。本发明利用传统中医理论,讲究整体观,通过调节全身气血生成,补精益髓,调节血液循环,营养神经,可改善突出物与神经之间的关系,松弛腰背部肌肉,恢复腰椎的正常列线,消除渗出、水肿,缓解疼痛,改善纤维软骨,并且具有起效快、有效率高、疗效确切、治疗疗程、无毒副作用,价格低,给药方便,安全有效,病人易于接受等优势。
具体实施方式
腰为肾之府,乃肾之精气所溉之域。肾与膀胱相表里,足太阳经过之。此外,任、督、冲、带诸脉,亦布其间,故内伤则不外肾虚。而外感风寒湿热诸邪,以湿性粘滞,湿流下,最易痹着腰部,所以外感总离不开湿邪为患。内外二因,相互影响,如《杂病源流犀烛·腰痛病源流》指出:“腰痛,精气虚而邪客病也。……肾虚其本也,风寒湿热痰饮,气滞血瘀闪挫其标也,或从标,或从本,贵无失其宜而已。”说明肾虚是发病关键所在,风寒湿热的痹阻不行,常因肾虚而客,否则虽感外邪,亦不致出现腰痛。至于劳力扭伤,则和瘀血有关,临床上亦不少见。
因此,本发明提供了一种治疗肾虚型腰椎间盘突出的中药制剂,其中,包括以下原料药材:苦蘵、木香、乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加、沙棘、鹿茸、淫羊藿、巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁、肾蕨、红直当药、韭菜子和黄芪 。
其中,上述原料药材的药理如下:
木香:辛,苦,性温;归脾,大肠,三焦经。《本草纲目》云:“木香,乃三焦气分之药,能升降诸气。诸气膹郁,皆属于肺,故上焦气滞用之者,乃金郁则泄之也;中气不运,皆属于脾,故中焦气滞宜之者,脾胃喜芳香也;大肠气滞则后重,膀胱气不化则癃淋,肝气郁则为痛,故下焦气滞者宜之,乃塞者通之也”。功效:行气,止痛,健脾,消食。主治:行气止痛;调中导滞。主胞胁胀满足,脘腹胀痛,嗳吐泄泻,痢疾后重。用于胸脘胀痛、泻痢后重、食积不消、不思饮食。木香辛温香散,能升能降,通理三焦之气,尤其善行胃肠之气而止痛,兼有健脾消食之功,凡脾胃大肠气滞所致诸证均为常用之品。
乌药:性味辛,温。入胃,肾经。舒气,温中,散寒,止痛。1.寒凝气滞之胸腹诸痛证。该品味辛行散,性温祛寒,入肺而宣通,入脾而宽中,故能行气散寒止痛。2.尿频,遗尿。该品辛散温通,入肾与膀胱而温肾散寒,缩尿止遗。乌药对心肌有兴奋作用,其挥发油内服有兴奋心肌、加速回流循环、升压及发汗作用,亦有兴奋大脑皮质、促进呼吸作用,局部涂用可使血管扩张、加快血液循环、缓解复合肌肉痉挛性疼痛作用。
天仙藤:苦,温;入肝、脾、肾经。《本草图经》:"解风劳。得麻黄则治伤寒发汗,与大黄同服堕胎气。"《本草再新》:"凉血活血,去风利湿,走经络,兼治腰腿肿疼。"行气化湿,活血止痛。治胃痛,疝气痛,妊娠水肿,产后血气腹痛,风湿疼痛。 行气活血,止痛,利尿。妊娠水肿,胸腹痛,疝痛,风湿痛。天仙藤,流气活血,治一切诸痛之药也。人身之气,顺则和平,逆则痛闷作矣。如杨氏《直指方》天仙藤治痰注臂痛,气留疝痛,瘕聚,奔豚腹痛,产后血气腹痛,他如妊娠水肿,面浮气促,男子风劳,久嗽不愈,悉以此药治之,无不寝安。盖谓其善于流行血气故也。观书所论主治,止属妊娠子肿、腹痛、风痨等症,而于他症则未及焉。即其所治之理,亦不过因味苦主于疏泄,性温得以通活,故能活血通道,而使水无不利,风无不除,血无不活,痛与肿均无不治故也。
九香虫:性温,味咸;归肝、脾、肾经。《本草新编》:“九香虫,虫中之至佳者、入丸散中,以扶衰弱最宜。但不宜入于汤剂)以其性滑,恐动大便耳。九香虫亦兴阳之物,然非人参。白术、巴戟天。肉苁蓉、破故纸之类,亦未见其大效也。”理气止痛,温中助阳。用于胃寒胀痛,肝胃气痛,肾虚阳痿,腰膝酸痛。九香虫对金黄色葡萄球菌、伤寒杆菌、副伤寒杆菌、福氏痢疾杆菌有较强的抗菌作用;并有促进机体新陈代谢作用。
刀豆:性温,性平,味甘,无毒。《中药材手册》:“补肾,散寒,下气,利肠胃,止呕吐。治肾气虚损,肠胃不和,呕逆,腹胀,吐泻。”温中下气。利肠胃,止呕吐,益肾补元气。已发现刀豆子具有脂氧酶(lipoxygenase)激活作用,其有效成分是刀豆毒素。刀豆球蛋白A(Con A)是一种植物血凝素,具有强力的促有丝分裂作用,有较好的促淋巴细胞转化反应的作用,其促淋巴细胞转化最适浓度为40-100μg/ml,能沉淀肝糖原,一般人群均可食用,尤适于肾虚腰痛、气滞呃逆、风温腰痛、小儿疝气等症患者食用。
川芎:味辛,性温;归肝、胆、心经。《神农本草经》:“主中风入脑头痛、寒痹,筋脉缓急,金疮,妇人血闭无子。”《日华子本草》:“治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破症结宿血,养新血,长肉,鼻洪,吐血及溺血,痔瘘,脑痈发背,瘰疬瘿赘,疮疥,及排脓消瘀血。”气香升散。具有活血行气,祛风止痛的功效。主治月经不调,痛经,经闭,难产,胞衣不下,产后恶露腹痛,肿块,心胸胁疼痛,跌打损伤肿痛,头痛眩晕目暗,风寒湿痹 ,肢体麻木,痈疽疮疡。用于感冒头痛,偏正头痛等症。川芎辛香善升,能上行头目巅顶,具有祛风止痛作用,为治头风头痛要药。此外,临床常用该品治疗冠心病心绞痛。川芎辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。川芎嗪能扩张冠状动脉,增加冠状动脉血流量,改善心肌的血氧供应,并降低心肌的耗氧量;川芎嗪可扩张脑血管,降低血管阻力,显著增加脑及肢体血流量,改善微循环;能降低血小板表面活性,抑制血小板凝集,预防血栓的形成。
姜黄:味辛、苦,性温,归肝、脾经,《本草纲目》:“姜黄,近时以扁如干姜形者为片子姜黄,圆如蝉腹形者为蝉肚郁金,并可浸水染色,蒁形虽似郁金,面色不黄也。”《本草求原》:“姜黄,益火生气,辛温这火化气,气生化则津液行于三阴三阳;清者注于肺,浊者注于经、溜于海,而血自行,是理气散结而兼泄血也。”具有破血行气,通经止痛的功效。用于血滞经闭,行经腹痛,胸胁剌痛,风湿痹痛,肩臂疼痛,跌扑损伤等证。用鼠Dalton氏淋巴腹水瘤细胞进行组织培养及在体实验,姜黄醇提物能抑制癌细胞生长。姜黄提取物、姜黄素、挥发油、姜黄酮以及姜烯、龙脑和倍半萜醇等,都有利胆作用,能增加胆汁的生成和分泌,并能促进胆囊收缩,而以姜黄素的作用为最强。
五灵脂:甘,温。活血散瘀,炒炭止血。用于心腹淤血作痛,痛经,血瘀经闭,产后淤血腹痛;炒炭治崩漏下血;外用治跌打损伤,蛇、虫咬伤。五灵脂苦泄温通,“通利气脉”,“通则不痛。”故《本草经疏》谓之“血滞经脉,气不得行,攻刺疼痛等证,在所必用。”应用时,可单味服用,如《鸡峰普济方》治卒暴心痛,不可忍者,用本品为末,热酒或醋汤下。若与蒲黄相须而用,治血滞心痛及产后恶露不下,少腹作痛,其效益彰,如《经效方》失笑散。若与功兼活血行气之延胡索、没药和香附同用,以治血瘀气滞,脘痛如刺者,益增化瘀行气止痛之效,如《医学心悟》手拈散。近来常有用本品配活血、行气、通阳之品,治冠心病心绞痛者,亦有良好效果。用于崩漏下血诸证。五灵脂炒用有止血之效,且无留瘀之弊,出血夹瘀者用之,尤能化瘀止血,可单味内服。治血崩诸药不能止者,用五灵脂炒令烟尽为末,温酒调下,可“去故生新”。
夏天无:苦、微辛,温。归肝经。《全国中草药汇编》:“祛风湿,降血压。主治风湿性关节炎、腰肌劳损,高血压病,脑血管意外引起偏瘫。”功能活血通络,行气止痛。用于中风偏瘫,跌扑损伤,风湿性关节炎,坐骨神经痛。夏天无生物碱可使麻醉犬脑与下肢血流量增加,血管阻力减低(经统计学处理均有显著差异),血压轻度下降,提示其有扩张脑血管和下肢血管的作用。1%夏大无注射液0.3ml加入15ml平滑肌溶液中肠管节律性收缩增强,张力增强,甚至是痉挛性收缩,提示对大白鼠离体平滑肌有兴奋作用。对于坐骨神经痛、风湿性关节炎、骨折及扭伤、小儿麻痹症等,有止痛,消肿,缓解关节僵硬,促进患肢功能恢复,加速骨折愈合等效果。
丹参:味苦、性寒,入心、肝经,有活血化瘀、祛瘀生新、凉血宁心的作用,主要用于血瘀气滞之心胸,胸胁刺痛,胸闷气短,腹胀;妇女气血不和之月经不调,经痛经闭;气血瘀滞,心腹疼痛等症状,丹参可以减少作为内脏脂肪和睾丸周围脂肪,减轻胰岛素分泌和糖代谢的早期损害。加强心肌收缩力、改善心脏功能,不增加心肌耗氧量。扩张冠脉,增加心肌血流量;扩张外周血管,血流增加;脑血流量下降,提高纤溶酶活性;延长出、凝血时间;抑制血小板聚集(提高血小板内cAMP水平抑制TXA2合成);改善血液流变学特性(血粘度降低、红细胞电泳时间缩短)。丹参片是活血化瘀、理气止痛的中成药。主要用于心绞痛、高血压、颈椎病以及胸中憋闷等病症。而且其药效可靠、丹参片的副作用小。但是也不能吃的过于频繁。因为长期服用复方丹参片可能引起血钾含量降低,产生低血钾症。
牛膝:味苦,酸,性平;归肝,肾经。《日华子本草》:“治腰膝软怯冷弱,破症结,排脓止痛,产后心腹痛并血运,落胎,壮阳。”《滇南本草》:“治疔疮、痈疽,敷患处。亦能打胎。同猪肉煨食之,能明目。”具有补肝肾,强筋骨,活血通经,引火(血)下行,利尿通淋的功效。
缬草:辛、甘、温;归心、肝经。《四川中药志》:"治脑神经及心、胃衰弱,慢性神经失常及尿崩。"治心神不安,胃弱,腰痛,月经不调,跌打损伤。
合欢皮:甘,平;入心、肝经。《日华子本草》:“煎膏,消痈肿并续筋骨。”《神农本草经》:“合欢,味甘平。主安五脏,利心志,令人欢乐无忧……生山谷。” 抗过敏合欢皮煎剂大鼠灌胃给药可抑制其腹膜肥大细胞脱颗粒,体外试验也有类似作用。合欢皮煎剂可明显抑制抗原(马血清)对大 鼠的致敏过程和抗体产生过程。合欢皮为豆科植物合欢的树皮,合欢皮别名合昏皮、夜台皮、合欢木皮,合欢皮有安神解郁、活血消痈的功效,合欢皮有治疗心神不安、忧郁、不眠、内外痈疡、跌打损伤的作用。
灵芝:灵芝作药物的灵芝为赤芝和紫芝,其药性为甘,平。归心、肝、脾、肺、肾五经。主治虚劳、咳嗽、气喘、失眠、消化不良,恶性肿瘤等。对人肝癌细胞具有细胞毒作用,也能抑制组织胺的释放,具有保肝作用和具有抗过敏作用等。无论在肝脏损害发生前还是发生后,服用灵芝都可保护肝脏,减轻肝损伤。灵芝能促进肝脏对药物、毒物的代谢,对于中毒性肝炎有确切的疗效。动物实验和临床试验均表明,灵芝可有效地扩张冠状动脉,增加冠脉血流量,改善心肌微循环,增强心肌氧和能量的供给,因此,对心肌缺血具有保护作用,可广泛用于冠心病、心绞痛等的治疗和预防。灵芝所含的多糖、多肽等有着明显的延缓衰老功效。提取物能激发运动性抑制,使运动性降低,使协调运动失调、呈现用量依赖性镇病效果,对环已巴比妥睡眠作用能缩短睡眠时间,能延长中枢兴奋药咖啡因致痉挛及死亡的时间,这些结果表明,灵芝对中枢呈抑制性作用。
山药:味甘,性平,入肺、脾、肾经,具有健脾补肺、益胃补肾、固肾益精、聪耳明目、助五脏、强筋骨、长志安神、延年益寿的功效,主治脾胃虚弱、倦怠无力、食欲不振、久泄久痢、肺气虚燥、痰喘咳嗽、肾气亏耗、腰膝酸软、下肢痿弱、消渴尿频、遗精早泄、带下白浊、皮肤赤肿、肥胖等证。麸炒山药补脾健胃。用于脾虚食少,泄泻便溏,白带过多。该品养阴能助湿,所以湿盛中满、或有积滞、有实邪者不宜。
甘草:性味甘,平。入脾、胃、肺经。《本经》曰:“主五脏六府寒热邪气,坚筋骨,长肌肉,倍力,金疮肿,解毒”。人阴(不)《药性论》曰:“主腹中冷痛,治惊痫,除腹胀满;补益五脏;制诸药毒;养肾气内伤,令痿;主妇人血沥腰痛;虚而多热;加而用之”。可益气补中,缓急止痛,润肺止咳,泻火解毒,调和诸药。主倦怠食少,肌瘦面黄,心悸气短,腹痛便溏,四肢挛急疼痛,脏躁,咳嗽气喘,咽喉肿痛,痈疮肿痛,小儿胎毒,及药物、食物中毒。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。西医药理发现,甘草剂有抗炎和抗变态反映的功能,因此在西医临床上主要作为缓和剂。缓解咳嗽,祛痰,治疗咽痛喉炎;甘草或甘草次酸有去氧皮质酮类作用,对慢性肾上腺皮质功能减退症有良好功效;甘草制剂能促进胃部粘液形成和分泌,延长上皮细胞寿命,有抗炎活性,常用于慢性溃疡和十二指肠溃疡的治疗;甘草的黄酮具有消炎、解痉和抗酸作用;甘草也是人丹的主要原料之一。
刺五加:味辛、苦、微甘,性温,入脾、肾、心经,具有益气健脾,补肾安神,祛风除湿的功效,用于风寒湿痹、腰膝疼痛、筋骨痿软、行动迟缓、体虚羸弱、跌打损伤、骨折、水肿、脚气、阴下湿痒等证。刺五加甘A为胡萝卜素,人蔘中也含这类成分。在人体内能促进胆固醇的排泄,可防治血液中胆固醇含量过高症。刺五加甘B为紫丁香素( Syringin ),是刺五加的主要强壮成分,有促性腺、抗辐射、抗疲劳等作用,具有与人蔘皂素相似的生理活性。刺五加含超氧化歧化酵素SOD(Superoxide dimutase)复合物,SOD具有良好的抗氧化功能,可以增强人体免疫以及抵抗自由基攻击的效果,具有抗氧化作用,可增强人体免疫力、防止老化及促进健康。
沙棘:沙棘果和油具有很高的药用价值,可降低胆固醇,缓解心绞痛发作,还有防治冠状动脉粥样硬化性心脏病的作用;有祛痰、止咳、平喘和治疗慢性气管炎的作用;能治疗胃和十二指肠溃疡以及消化不良等,对慢性浅表性胃炎、萎缩性胃炎、结肠炎等病症疗效显著;对烧伤、烫伤、刀烧、冻伤有很好的治疗作用;对妇女宫颈糜烂有良好的治疗效果。沙棘果实中含有异鼠李素及其糖甙、槲皮素、山柰酚等7种黄桐物质,具有止咳、平喘祛痰、扩张冠状血管、降低胆固醇的效能,常用于治疗缺血性心脏病,对治疗心绞痛有效率达94%。沙棘中SOD活性成分丰富,每克沙棘鲜果SOD含量达到2746.0个酶单位,其含量是人参的4倍。它可以阻断因体内物质过氧化产生的自由基,而这种自由基与人体衰老、疾病的发生密切相关。
鹿茸:甘、咸,温。归肾、肝经。壮肾阳,补精髓,强筋骨,调冲任,托疮毒。主治肾虚、头晕、耳聋、目暗、阳痿、滑精、宫冷不孕、羸瘦、神疲、畏寒、腰脊冷痛、筋骨痿软、崩漏带下、阴疽不敛及久病虚损等症。鹿茸含有比人参更丰富的氨基酸、卵磷脂、维生素和微量元素等。鹿茸性温而不燥,具有振奋和提高机体功能,对全身虚弱、久病之后患者,有较好的保健作用。鹿茸可以提高机体的细胞免疫和体液免疫功能,促进淋巴细胞的转化,具有免疫促进剂的作用。它能增加机体对外界的防御能力,调节体内的免疫平衡而避免疾病发生和促进创伤愈合、病体康复,从而起到强壮身体、抵抗衰老的作用。
淫羊藿:味辛、甘,性温,入肝、肾经,《本经》:“主阴痿绝伤,茎中痛。利小便,益气力,强志。”《日华子本草》:“治一切冷风劳气,补腰膝,强心力,丈夫绝阳不起,女子绝阴无子,筋骨挛急,四肢不任,老人昏耄,中年健忘。”具有补肾阳,强筋骨,祛风湿的作用,用于肾虚阳痿、遗精早泄、腰膝痿软、肢冷畏寒;寒湿痹痛或四肢拘挛麻木等证,淫羊藿能增强性腺功能, 促进雌激素分泌和卵泡发育及促进输卵管黏膜增厚,延长产蛋高峰期 ,同时还能促进阳虚动物体内 DNA 合成,使其合成率接近正常水平。
巴戟天:味辛、甘,性温,归肝、肾经,《药性论》:“治男子梦交泄精,强阴,除头面中风,主下气,大风血癞。”具有补肾助阳,强筋壮骨,祛风除湿的功效。主治肾虚阳痿,遗精早泄,少腹冷痛,小便不禁,宫冷不孕,风寒湿痹,腰膝酸软,风湿肢气等证。盐巴戟天擅入肾经,补肾功强,用于肾亏阳蒌、早泄不孕,制巴戟天性缓毒去,使功更专,用治风冷腹痛,关节酸痛,小便失禁等证。同属植物Morinda lucida的提取物对麻醉猫有显著降压作用,对不麻醉大鼠也有降压作用,但维持时间短,并有一些安定与利尿作用。巴戟天具有抑制小鼠胸腺萎缩及增加其血中白细胞数的功能。巴戟天水煎液用药浓度250g/kg体重时,未见动物死亡,对大肠杆菌SOS应答系统无明显影响,提示巴戟天可能无诱变或致诱变的遗传作用。
杜仲:味甘、微辛,性温,入肝、肾经。《玉楸药解》:"益肝肾,养筋骨,去关节湿淫。治腰膝酸痛,腿足拘挛。"《神农本草经》:“主腰脊痛、补中益精气、坚筋骨、强志、除阴下痒湿、小便余沥。”《药性论》:“治肾冷臀腰痛,腰病人虚而身强直,风也。腰不利加而用之。”杜仲具有补肝肾,强筋骨,清除体内垃圾,加强人体细胞物质代谢,防止肌肉骨骼老化,平衡人体血压,分解体内胆固醇,降低体内脂肪,恢复血管弹性,利尿清热,广谱抗菌,兴奋中枢神经,提高白血球药理作用。杜仲的叶和皮含有蛋白质、脂肪、维生素和矿物质等营养成分。杜仲游离氨基酸极少,含有的少量蛋白质,是和绝大多数食品类似的完全蛋白,即能够水解检出对人体必需的8种氨基酸。杜仲对免疫系统、内分泌系统、中枢神经系统、循环系统和泌尿系统都有不同程度的调节作用,杜仲能兴奋垂体-肾上腺皮质系统,增强肾上腺皮质功能。动物实验表明,杜仲含有一种可促进人体的皮肤、骨骼、肌肉中的蛋白质胶原的合成与分解的特殊成分,具有促进代谢、防止衰退的功能。
仙茅:辛,温;入肾、肝经。《日华子本草》:“治一切风气,补五劳七伤,开胃下气。”《滇南本草》:“治妇人红崩下血,攻痈疽,排脓。”补肾阳,强筋骨,散寒湿。治阳萎精冷,小便失禁,崩漏,心腹冷痛,腰脚冷痹,痈疽,瘰疬,阳虚冷泻,阳痿精寒,腰膝风冷,筋骨痿痹等症。仙茅具有调节免疫、抗氧化、保肝、抗高血糖、补肾壮阳及抗骨质疏松、抗炎和适应原样等作用。在服用仙茅的期间,要注意以下几点:保持良好的作息习惯,尽量避免熬夜。少吃辛辣或者刺激性食物。积极参加户外运动,放松心情。不要给自己太大的压力,学会合理减压。
肉苁蓉:甘、咸,温;归肾、大肠经。《药性论》:“益髓,悦颜色,延年,治女人血崩,壮阳,大补益,主赤白下。”《日华子本草》:“治男绝阳不兴,女绝阴不产,润五脏,长肌肉,暖腰膝,男子泄精,尿血,遗沥,带下阴痛。”补肾阳,益精血,润肠通便。用于阳痿,不孕,腰膝酸软,筋骨无力,肠燥便秘。肉苁蓉含有丰富的生物碱、结晶性的中性物质、氨基酸、微量元素、维生素等成分。能补肾阳、益精血,能抑制“阳虚”症状的出现,防止体重减轻及女子月经不调、闭经不孕等疾病。
菟丝子:气味辛,甘,平,无毒。《别录》:"养肌强阴,坚筋骨,主茎中寒,精自出,溺有余沥,口苦燥渴,寒血为积。"《日华子本草》:"补五劳七伤,治泄精,尿血,润心肺。"补肾益精,养肝明目。适用于肝肾不足的腰膝筋骨酸痛,腿脚软弱无力、阳痿遗精、呓语、小便频数、尿有余沥、头晕眼花、视物不清、耳鸣耳聋以及妇女带下、习惯性流产等症。菟丝子有提高果蝇性活力的作用, 使其交配率明显增加,其作用强弱与给药浓度成正相关。浸剂给麻醉犬静脉注射,有使血压下降的作用。
核桃仁:味甘,性温,入肾、肺、大肠经,具有补肾益精,温肺定喘,润肠通便的作用,用于肾气亏虚之腰痛腿软,头晕乏力,尿频遗精,消渴,肺肾两虚之咳喘,老年人气虚及产后血亏津少而致的肠燥便秘,跌打损伤,疮疡痈肿等证。核桃中的磷脂,对脑神经有很好保健作用。核桃油含有不饱和脂肪酸,有防治动脉硬化的功效。核桃仁中含有锌、锰、铬等人体不可缺少的微量元素。人体在衰老过程中锌、锰含量日渐降低,铬有促进葡萄糖利用、胆固醇代谢和保护心血管的功能。核桃仁的镇咳平喘作用也十分明显,冬季,对慢性气管炎和哮喘病患者疗效极佳。
韭菜子:辛,甘,温;归肾,肝经。韭菜子有温补肝肾,壮阳固精,暖腰膝的功效,治阳痿、遗精、白带白淫,遗尿,小便频数、腰膝酸软、冷痛。韭菜子用于肝肾不足,肾阳虚衰所致的阳痿,腰膝酸软疼痛。韭菜子有补肝肾、暖腰膝、壮肾阳的功能。韭菜子可单味用,或与菟丝子、补骨脂、淫羊藿等补肾壮阳之品配合使用。韭菜子尚可用于小便淋浊,可单用或与车前子同用。韭菜子用于肾气不固所致的遗精、尿频、遗尿、带下清稀。韭菜子有补肾温阳,固精缩尿的功效,如《千金要方》单用本品研末或作蜜丸服,肾虚遗精带下。韭菜子配伍补骨脂、益智仁等补肾缩尿药,治肾与膀胱虚冷,小便频数。
苦蘵:性味:苦,寒。主治:清热解毒,消肿利尿。用于咽喉肿痛,腮腺炎,急慢性气管炎,肺脓疡,痢疾,睾丸炎,小便不利;外用治脓疱疮。
南苜蓿:性味:全草:苦、微涩,平。根:苦、微涩,寒。主治:全草:清热利尿。治膀胱结石。根:清热利尿,退黄。治黄疸,尿路结石。
瑞连草:性味:苦、酸,凉。主治:清热解毒。
匐地龙:性味:微苦,凉。主治:利尿排石,清热解毒,理脾消积。用于尿路结石,胆道结石,黄疸型传染性肝炎,狂犬病,蕈子中毒,小儿疳积,牙龈肿毒,痈肿疔疮。
繁缕:性味:甘、酸,凉。主治:清热解毒,化瘀止痛,催乳。用于肠炎,痢疾,肝炎,阑尾炎,产后瘀血腹痛,子宫收缩痛,牙痛,头发早白,乳汁不下,乳腺炎,跌打损伤,疮疡肿毒。
乌蔹莓:性味:苦、酸,寒。主治:解毒消肿,活血散瘀,利尿,止血。用于咽喉肿痛、目翳,咯血,血尿,痢疾;外用治痈肿,丹毒,腮腺炎,跌打损伤,毒蛇咬伤。
肾蕨:性味:甘、淡,微涩,凉。主治:清热利湿,宁肺止咳,软坚消积。用于感冒发热,咳嗽,肺结核咯血,痢疾,急性肠炎,小儿疳积,中毒性消化不良,泌尿系感染;外用治乳腺炎,淋巴结炎。
红直当药:性味:苦,凉。归经:入心、肺、脾经。主治:治肺炎、黄疸、梅毒、疮肿、咽肿,疥癣。
黄芪:性味:甘,温。归经:归肺、脾经。主治:补气固表,利尿托毒,排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,痈疽难溃,久溃不敛,血虚痿黄,内热消渴;慢性肾炎蛋白尿,糖尿病。
其中,所述中药制剂中各原料药材的重量份数比可以优选为:苦蘵12~30份、木香15~35份、乌药10~25份、南苜蓿17~30份、天仙藤10~26份、九香虫15~30份、瑞连草14~28份、刀豆12~22份、川芎15~27份、姜黄15~25份、五灵脂18~30份、夏天无17~26份、匐地龙16~27份、丹参18~30份、牛膝15~25份、缬草16~25份、合欢皮10~20份、繁缕15~26份、灵芝12~25份、山药11~26份、乌蔹莓15~25份、甘草15~28份、刺五加15~30份、沙棘12~27份、鹿茸15~27份、淫羊藿15~30份、巴戟天10~20份、杜仲12~25份、仙茅15~25份、肉苁蓉15~30份、菟丝子10~28份、核桃仁16~30份、肾蕨17~35份、红直当药18~27份、韭菜子10~20份和黄芪15~30份。
其中,所述中药制剂中各原料药材的重量份数比还可以优选为:苦蘵15~26份、木香18~30份、乌药15~22份、南苜蓿19~27份、天仙藤15~25份、九香虫17~28份、瑞连草15~25份、刀豆15~20份、川芎17~25份、姜黄18~22份、五灵脂18~25份、夏天无19~25份、匐地龙17~25份、丹参19~25份、牛膝17~22份、缬草17~20份、合欢皮12~20份、繁缕17~25份、灵芝15~22份、山药12~25份、乌蔹莓17~22份、甘草16~25份、刺五加17~25份、沙棘15~25份、鹿茸17~25份、淫羊藿15~25份、巴戟天12~20份、杜仲15~28份、仙茅17~22份、肉苁蓉17~25份、菟丝子12~25份、核桃仁18~28份、肾蕨19~30份、红直当药19~25份、韭菜子12~20份和黄芪15~28份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵22份、木香20份、乌药18份、南苜蓿25份、天仙藤21份、九香虫23份、瑞连草17份、刀豆19份、川芎20份、姜黄20份、五灵脂23份、夏天无22份、匐地龙19份、丹参22份、牛膝19份、缬草18份、合欢皮18份、繁缕23份、灵芝20份、山药18份、乌蔹莓19份、甘草23份、刺五加21份、沙棘22份、鹿茸23份、淫羊藿17份、巴戟天15份、杜仲25份、仙茅19份、肉苁22份、菟丝子18份、核桃24份、肾蕨23份、红直当药22份、韭菜子17份和黄芪25份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵25份、木香19份、乌药22份、南苜蓿23份、天仙藤25份、九香虫25份、瑞连草17份、刀豆16份、川芎22份、姜黄20份、五灵脂21份、夏天23份、匐地龙24份、丹参22份、牛膝19份、缬草19份、合欢皮15份、繁缕22份、灵芝21份、山药21份、乌蔹莓19份、甘草20份、刺五加22份、沙棘23份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉21份、菟丝子13份、核桃仁25份、肾蕨20份、红直当药25份、韭菜子15份和黄芪18份。
其中,所述中药制剂中各原料药材的重量份数比又可以优选为:苦蘵17份、木香24份、乌药22份、南苜蓿23份、天仙藤25份、九香虫28份、瑞连草22份、刀豆19份、川芎23份、姜黄20份、五灵脂23份、夏天无21份、匐地龙24份、丹参22份、牛膝18份、缬草19份、合欢皮15份、繁缕22份、灵芝20份、山药24份、乌蔹莓21份、甘草18份、刺五加24份、沙棘18份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉24份、菟丝子19份、核桃仁24份、肾蕨25份、红直当药20份、韭菜子15份和黄芪22份。
其中,当所述中药的剂型为片剂时,其制备方法包括以下步骤:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为85%~95%的乙醇,加热回流4~6小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2~4倍的醇浓度为90%~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~3小时,粉碎,过筛,获得400目~500目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1~0.2倍的微晶纤维素、0.15~0.3倍乳糖、0.2~0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.025~0.04倍硬脂酸镁,整粒,压片,制成。
其中,当所述中药的剂型为口服液时,其制备方法包括以下步骤:
第一步,将南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加和沙棘混合,加相对于混合物6~8倍量醇浓度为90%~95%的乙醇回流提取2~3次,每次3~5小时,分别过滤,各次滤液合并,回收乙醇,浓缩至70℃相对密度为1.37~1.39的膏体,备用;
第二步,将剩余原料药材按比例混合,加相对于混合物5~7倍量水,煮沸4~6小时,过滤,浓缩至70℃相对密度为1.32~1.36的膏体;
第三步,将第一步、第二步获得的所述膏体混合,70℃~80℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为65%~80%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为24~48小时,冷藏温度为3℃~6℃;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.2~0.35;所述脱醇膏体与所述活性炭的重量比为1∶0.003~0.005;所述加热处理的时间为70~90分钟,温度为150℃~180℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
其中,当所述中药的剂型为贴片剂时,其制备方法包括以下步骤,
第一步,将乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无和匐地龙按所述比例混合,用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流2~3小时后提取,过滤,得第一过滤液;将滤渣再次用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流1~2小时后提取,过滤,得第二过滤液;合并第一过滤液和第二过滤液,减压回收乙醇并浓缩至药液浓度为0.6~0.8g生药/mL,经体积为5L的大孔吸附树脂柱洗脱,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为80%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁和肾蕨按所述比例混合,加相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇加热回流提取2~3次,提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~80℃的条件下减压浓缩至60℃时相对密度为1.20~1.24的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~3倍的水溶解,加热煎煮3~5小时,过滤;将滤渣再次用相对于获得的混合物质量的1~2倍的水溶解,加热煎煮1~2小时,过滤;合并两次的过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,加入相对于所述中药各原料药材质量之和的1~2倍的橡胶、1~2倍的松香,混合,制成涂料,进行涂膏,切断,盖衬,切片,即获得所述贴片剂。
实施例1 片剂
本发明口服片剂的制作过程为:取苦蘵220g、木香200g、乌药180g、南苜蓿250g、天仙藤210g、九香虫230g、瑞连草170g、刀豆190g、川芎200g、姜黄200g、五灵脂230g、夏天无220g、匐地龙190g、丹参220g、牛膝190g、缬草180g、合欢皮180g、繁缕230g、灵芝200g、山药180g、乌蔹莓190g、甘草230g、刺五加210g、沙棘220g、鹿茸230g、淫羊藿170g、巴戟天150g、杜仲250g、仙茅190g、肉苁220g、菟丝子180g、核桃240g、肾蕨230g、红直当药220g、韭菜子170g和黄芪250g;
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量5倍的醇浓度为90%的乙醇,加热回流4小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量3倍的醇浓度为95%的乙醇,加热回流2小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎3小时,粉碎,过筛,获得400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.2倍的微晶纤维素、0.2倍乳糖、0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.03倍硬脂酸镁,整粒,压片,制成。
实施例2 口服液
本发明口服液的制作过程为:取苦蘵250g、木香190g、乌药220g、南苜蓿230g、天仙藤250g、九香虫250g、瑞连草170g、刀豆160g、川芎220g、姜黄200g、五灵脂210g、夏天230g、匐地龙240g、丹参220g、牛膝190g、缬草190g、合欢皮150g、繁缕220g、灵芝210g、山药210g、乌蔹莓190g、甘草200g、刺五加220g、沙棘230g、鹿茸190g、淫羊藿230g、巴戟天180g、杜仲250g、仙茅200g、肉苁蓉210g、菟丝子130g、核桃仁250g、肾蕨200g、红直当药250g、韭菜子150g和黄芪180g;
第一步,将南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加和沙棘混合,加相对于混合物7倍量醇浓度为95%的乙醇回流提取3次,每次4小时,分别过滤,各次滤液合并,回收乙醇,浓缩至70℃相对密度为1.38的膏体,备用;
第二步,将剩余原料药材按比例混合,加相对于混合物5倍量水,煮沸5小时,过滤,浓缩至70℃相对密度为1.35的膏体;
第三步,将第一步、第二步获得的所述膏体混合,80℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为70%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为48小时,冷藏温度为6℃;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.3;所述脱醇膏体与所述活性炭的重量比为1∶0.004;所述加热处理的时间为90分钟,温度为180℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
实施例3 贴片剂
本发明外用贴片剂的制作过程为:苦蘵170g、木香240g、乌药220g、南苜蓿230g、天仙藤250g、九香虫280g、瑞连草220g、刀豆190g、川芎230g、姜黄200g、五灵脂230g、夏天无210g、匐地龙240g、丹参220g、牛膝180g、缬草190g、合欢皮150g、繁缕220g、灵芝200g、山药240g、乌蔹莓210g、甘草180g、刺五加240g、沙棘180g、鹿茸190g、淫羊藿230g、巴戟天180g、杜仲250g、仙茅200g、肉苁蓉240g、菟丝子190g、核桃仁240g、肾蕨250g、红直当药200g、韭菜子150g和黄芪220g;
第一步,将乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无和匐地龙按所述比例混合,用相对于获得的混合物质量的5倍的醇浓度85%的乙醇溶解,加热回流2小时后提取,过滤,得第一过滤液;将滤渣再次用相对于获得的混合物质量的5倍的醇浓度85%的乙醇溶解,加热回流2小时后提取,过滤,得第二过滤液;合并第一过滤液和第二过滤液,减压回收乙醇并浓缩至药液浓度为0.7g生药/mL,经体积为5L的大孔吸附树脂柱洗脱,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为85%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁和肾蕨按所述比例混合,加相对于获得的混合物质量的3倍的醇浓度90%的乙醇加热回流提取3次,提取液合并,用管式离心机离心除杂,将除杂后的提取液于70℃的条件下减压浓缩至60℃时相对密度为1.20的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的3倍的水溶解,加热煎煮5小时,过滤;将滤渣再次用相对于获得的混合物质量的2倍的水溶解,加热煎煮1小时,过滤;合并两次的过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,加入相对于所述中药各原料药材质量之和的2倍的橡胶、2倍的松香,混合,制成涂料,进行涂膏,切断,盖衬,切片,即获得所述贴片剂。
急性毒性实验:
急性毒性试验:应用NIH小鼠40只,SPF级,雌雄各半,体重18~25g,进行急性毒性试验。小鼠随机分为两组,每组20只,即对照组和给药组,实验前禁食12小时;将本发明的实施例1制备的片剂溶解在水中,(浓度为5.74g生药/ml,最高浓度)灌胃,灌胃容积为5ml/kg(即单次给药剂量为28.7生药/kg),对照组给予等量生理盐水,一天给药2次,给药间隔时间6小时,给药后连续观察14天,并记录小鼠的的毒性反应及死亡数。实验结果表明:与对照组比较,给药后小鼠未见明显差异,实验连续观察14天,小鼠全身状况、饮食、饮水、体重增长均正常。小鼠口服灌胃本发明的片剂LD50>28.7生药/kg,每日最大给药量为57.4生药/kg/日。本发明的中药临床用药量为4.6g生药/日/人,成人体重以60KG计,平均用药剂量为0.077g生药/kg/日。按体重计:小鼠(平均体重以21g计)口服灌胃本发明的中药的耐受量为临床用量的745倍。因此本发明的中药急性毒性低,临床用药安全。
长期毒性实验:将本发明实施例2的口服液对小鼠按6.43、15.72和36.41g生药/kg连续用药16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明中药制剂对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明中药制剂对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
临床资料:
病例选择:取来源于本院骨科病人的200例肾虚型腰椎间盘突出患者,男117人,女83人;年龄20~68岁,病史5个月~7年;腰椎间盘中央突出型7例,L4-5椎间103例,L5-S1椎间67例,侧位突出11例; 病发于L3-4椎间12例。全部病例均经CT确诊。200例病人随机分为中药治疗组和中成药对照组,中药治疗组150人,男89人,女61人;中成药对照组50人,男28人,女22人。
诊断标准:
1.有腰部外伤、慢性劳损或受寒湿史。大部分患者在发病前有慢性腰痛史。常发生于青壮年。
2.腰痛向臀部及下肢放射,腹压增加(如咳嗽、喷嚏)时疼痛加重。
3.脊柱侧弯,腰理理弧度消失,病变部位椎旁有压痛,并向下肢放射,腰活动受限。
4.下肢受累神经支配区有感觉过敏或迟钝,病程长都可出现肌内萎缩直腿抬高或加强试验阳性,膝、跟腱反射减弱或消失,拇趾背伸力减弱。
5.X线摄片检查:脊柱侧弯,腰生理前凸消失,相邻边缘有骨赘增生。且根据中医望、闻、问、切辨证进一步诊断为肾虚型腰椎间盘突出。
治疗方法:
中药治疗组中:
片剂治疗组:服用本发明实施例1制备的片剂,每日3次,一次4片,每30天为1个疗程;
口服液治疗组:服用本发明实施例2制备的口服液,每日3次,30ml/次,每30天为一个疗程;
贴片剂治疗组:使用本发明实施例3制备的贴片剂,每日2次,早晚各贴一次,每30天为一个疗程。
中成药对照组:服用根痛平颗粒,每日2次,每次1袋,每袋12g,每30天为一个疗程。
疗效评价标准:
根据《中医骨伤科病症诊断疗效标准》进行疗效评估。治愈:症状完全消失或接近消失,直腿抬高试验可达85°左右,能恢复原来工作;显效:症状部分消失,直腿抬高试验超过70°,可恢复原来的工作;好转:症状部分消失,腰腿痛减轻,直腿抬高试验较治疗前显著改善,可担任较轻工作;无效:症状无明显减轻,不能参加工作。
治疗结果:
参见表1和表2,从表1可以看出,采用本发明的中药治疗肾虚型腰椎间盘突出,相对于中成药在治疗效果上,具有显著的改进;从表2可以看出,采用本发明的中药治疗肾虚型腰椎间盘突出,相对于中成药,在治疗疗程上显著缩短。
表1各组分别治疗4个疗程后临床疗效比较 例
| 组别 | 例数 | 治愈数 | 显效数 | 好转数 | 无效数 | 总有效率(%) |
| 片剂治疗组 | 50 | 21 | 23 | 5 | 1 | 98% |
| 口服液治疗组 | 50 | 21 | 22 | 7 | 0 | 100% |
| 贴片剂治疗组 | 50 | 19 | 24 | 7 | 0 | 100% |
| 中成药治疗组 | 50 | 7 | 15 | 21 | 7 | 86% |
表2 四组分别治疗4个疗程后治愈、显效和好转人数和时间比较 例(%)
| 组别 | 例数 | 第1个疗程 | 第2个疗程 | 第3个疗程 | 第4个疗程 |
| 片剂治疗组 | 49 | 8(16.3%) | 11(22.4%) | 14(28.6%) | 16(32.7%) |
| 口服液治疗组 | 50 | 9(18%) | 10(20%) | 14(28%) | 17(34%) |
| 贴片剂治疗组 | 50 | 7(14%) | 12(24%) | 15(30%) | 16(32%) |
| 中成药治疗组 | 43 | 2(4.7%) | 6(13.9%) | 9(20.9%) | 26(60.5%) |
根据上述表格内的临床统计可知,本发明提供的中药具有起效快、有效率高、疗效确切、安全性高、无毒副作用;同时对治疗组治愈、显效和好转人数的149例以及中成药治疗组治愈、显效和好转的43例患者随访1年半,结果统计,片剂治疗组49例中治愈21例和显效23例都无复发,好转的5例中复发1例,复发率为2.04%;口服液治疗组50例中治愈21例无复发,显效22例中复发1例,好转的7例中复发2例,复发率为6%;贴片剂治疗组50例中治愈19例无复发,显效24例中复发1例,好转的7例中复发2例,复发率为6%;中成药治疗组治愈、显效和好转人数43例,治愈的7例患者中复发1例,显效的15例患者中复发5例,好转的21例中复发11例,复发率39.5%;上述复发是指患者治疗效果达到治愈、显效或好转后,在随访的1年半中明显出现治疗前的症状。
典型病例:王某,女性,48岁,因腰痛半月,偶尔感到两下肢麻木入院,经检查初步判断为腰椎间盘突出,X线摄片检查为:脊柱侧弯,腰生理前凸消失,相邻边缘有骨赘增生,确诊为腰椎肩盘突出,然后根据中医望闻问切进一步确诊为肾虚型腰椎间盘突出。服用本发明中药制剂实施例1的片剂,每日3次,每次4片,治疗2个月基本治愈,继续服药半个月治愈,随访1年半未复发。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (9)
1.一种治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,包括以下原料药材:苦蘵、木香、乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加、沙棘、鹿茸、淫羊藿、巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁、肾蕨、红直当药、韭菜子和黄芪。
2.根据权利要求1所述的治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,所述中药制剂中各原料药材的重量份数比为:苦蘵12~30份、木香15~35份、乌药10~25份、南苜蓿17~30份、天仙藤10~26份、九香虫15~30份、瑞连草14~28份、刀豆12~22份、川芎15~27份、姜黄15~25份、五灵脂18~30份、夏天无17~26份、匐地龙16~27份、丹参18~30份、牛膝15~25份、缬草16~25份、合欢皮10~20份、繁缕15~26份、灵芝12~25份、山药11~26份、乌蔹莓15~25份、甘草15~28份、刺五加15~30份、沙棘12~27份、鹿茸15~27份、淫羊藿15~30份、巴戟天10~20份、杜仲12~25份、仙茅15~25份、肉苁蓉15~30份、菟丝子10~28份、核桃仁16~30份、肾蕨17~35份、红直当药18~27份、韭菜子10~20份和黄芪15~30份。
3.根据权利要求1或2所述的治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,所述中药制剂中各原料药材的重量份数比为:苦蘵15~26份、木香18~30份、乌药15~22份、南苜蓿19~27份、天仙藤15~25份、九香虫17~28份、瑞连草15~25份、刀豆15~20份、川芎17~25份、姜黄18~22份、五灵脂18~25份、夏天无19~25份、匐地龙17~25份、丹参19~25份、牛膝17~22份、缬草17~20份、合欢皮12~20份、繁缕17~25份、灵芝15~22份、山药12~25份、乌蔹莓17~22份、甘草16~25份、刺五加17~25份、沙棘15~25份、鹿茸17~25份、淫羊藿15~25份、巴戟天12~20份、杜仲15~28份、仙茅17~22份、肉苁蓉17~25份、菟丝子12~25份、核桃仁18~28份、肾蕨19~30份、红直当药19~25份、韭菜子12~20份和黄芪15~28份。
4.根据权利要求1-3任一项所述的治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,所述中药制剂中各原料药材的重量份数比为:苦蘵22份、木香20份、乌药18份、南苜蓿25份、天仙藤21份、九香虫23份、瑞连草17份、刀豆19份、川芎20份、姜黄20份、五灵脂23份、夏天无22份、匐地龙19份、丹参22份、牛膝19份、缬草18份、合欢皮18份、繁缕23份、灵芝20份、山药18份、乌蔹莓19份、甘草23份、刺五加21份、沙棘22份、鹿茸23份、淫羊藿17份、巴戟天15份、杜仲25份、仙茅19份、肉苁22份、菟丝子18份、核桃24份、肾蕨23份、红直当药22份、韭菜子17份和黄芪25份。
5.根据权利要求1-4任一项所述的治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,所述中药制剂中各原料药材的重量份数比为:苦蘵25份、木香19份、乌药22份、南苜蓿23份、天仙藤25份、九香虫25份、瑞连草17份、刀豆16份、川芎22份、姜黄20份、五灵脂21份、夏天23份、匐地龙24份、丹参22份、牛膝19份、缬草19份、合欢皮15份、繁缕22份、灵芝21份、山药21份、乌蔹莓19份、甘草20份、刺五加22份、沙棘23份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉21份、菟丝子13份、核桃仁25份、肾蕨20份、红直当药25份、韭菜子15份和黄芪18份。
6.根据权利要求1-5任一项所述的治疗肾虚型腰椎间盘突出的中药制剂,其特征在于,所述中药制剂中各原料药材的重量份数比为:苦蘵17份、木香24份、乌药22份、南苜蓿23份、天仙藤25份、九香虫28份、瑞连草22份、刀豆19份、川芎23份、姜黄20份、五灵脂23份、夏天无21份、匐地龙24份、丹参22份、牛膝18份、缬草19份、合欢皮15份、繁缕22份、灵芝20份、山药24份、乌蔹莓21份、甘草18份、刺五加24份、沙棘18份、鹿茸19份、淫羊藿23份、巴戟天18份、杜仲25份、仙茅20份、肉苁蓉24份、菟丝子19份、核桃仁24份、肾蕨25份、红直当药20份、韭菜子15份和黄芪22份。
7.根据权利要求1-6任一项所述的治疗肾虚型腰椎间盘突出的中药制剂的制备方法,其特征在于,当所述中药的剂型为片剂时,其制备方法包括以下步骤:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量3~5倍的醇浓度为85%~95%的乙醇,加热回流4~6小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2~4倍的醇浓度为90%~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~3小时,粉碎,过筛,获得400目~500目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1~0.2倍的微晶纤维素、0.15~0.3倍乳糖、0.2~0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.025~0.04倍硬脂酸镁,整粒,压片,制成。
8.根据权利要求1-6任一项所述的治疗肾虚型腰椎间盘突出的中药制剂的制备方法,其特征在于,当所述中药的剂型为口服液时,其制备方法包括以下步骤:
第一步,将南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无、匐地龙、丹参、牛膝、缬草、合欢皮、繁缕、灵芝、山药、乌蔹莓、甘草、刺五加和沙棘混合,加相对于混合物6~8倍量醇浓度为90%~95%的乙醇回流提取2~3次,每次3~5小时,分别过滤,各次滤液合并,回收乙醇,浓缩至70℃相对密度为1.37~1.39的膏体,备用;
第二步,将剩余原料药材按比例混合,加相对于混合物5~7倍量水,煮沸4~6小时,过滤,浓缩至70℃相对密度为1.32~1.36的膏体;
第三步,将第一步、第二步获得的所述膏体混合,70℃~80℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为65%~80%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为24~48小时,冷藏温度为3℃~6℃;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.2~0.35;所述脱醇膏体与所述活性炭的重量比为1∶0.003~0.005;所述加热处理的时间为70~90分钟,温度为150℃~180℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
9.根据权利要求1-6任一项所述的治疗肾虚型腰椎间盘突出的中药制剂的制备方法,其特征在于,当所述中药的剂型为贴片剂时,其制备方法包括以下步骤,
第一步,将乌药、南苜蓿、天仙藤、九香虫、瑞连草、刀豆、川芎、姜黄、五灵脂、夏天无和匐地龙按所述比例混合,用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流2~3小时后提取,过滤,得第一过滤液;将滤渣再次用相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇溶解,加热回流1~2小时后提取,过滤,得第二过滤液;合并第一过滤液和第二过滤液,减压回收乙醇并浓缩至药液浓度为0.6~0.8g生药/mL,经体积为5L的大孔吸附树脂柱洗脱,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为80%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末;
第二步,将巴戟天、杜仲、仙茅、肉苁蓉、菟丝子、核桃仁和肾蕨按所述比例混合,加相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇加热回流提取2~3次,提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~80℃的条件下减压浓缩至60℃时相对密度为1.20~1.24的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末;
第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~3倍的水溶解,加热煎煮3~5小时,过滤;将滤渣再次用相对于获得的混合物质量的1~2倍的水溶解,加热煎煮1~2小时,过滤;合并两次的过滤液,减压浓缩除去水分,干燥并粉碎成粉末;
第四步,将第一步、第二步和第三步获得的粉末混合,加入相对于所述中药各原料药材质量之和的1~2倍的橡胶、1~2倍的松香,混合,制成涂料,进行涂膏,切断,盖衬,切片,即获得所述贴片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410311332.1A CN104043058A (zh) | 2014-07-02 | 2014-07-02 | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410311332.1A CN104043058A (zh) | 2014-07-02 | 2014-07-02 | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104043058A true CN104043058A (zh) | 2014-09-17 |
Family
ID=51496781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410311332.1A Pending CN104043058A (zh) | 2014-07-02 | 2014-07-02 | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104043058A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324332A (zh) * | 2014-11-22 | 2015-02-04 | 王竞鹏 | 一种治疗肝郁气滞型黄褐斑的中药制剂及其制备方法 |
| CN105031502A (zh) * | 2015-09-08 | 2015-11-11 | 王一鸣 | 一种治疗小儿肠炎的药物组合物及其制备方法 |
| TWI804073B (zh) * | 2020-11-27 | 2023-06-01 | 利統股份有限公司 | 用於治療抽筋和痙攣的調配物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1146343A (zh) * | 1995-09-25 | 1997-04-02 | 石建民 | 一种治疗椎间盘病的外敷膏 |
| CN102552705A (zh) * | 2011-11-19 | 2012-07-11 | 李永开 | 一种用于治疗腰椎间盘突出、股骨头坏死的中药胶囊 |
| CN103599379A (zh) * | 2013-12-03 | 2014-02-26 | 杨建勋 | 一种治疗肝肾亏虚型慢性骨髓炎的中药及其制备方法 |
| CN103860815A (zh) * | 2014-03-31 | 2014-06-18 | 张良洁 | 用于治疗自发性气胸的药物组合物及其制备方法 |
-
2014
- 2014-07-02 CN CN201410311332.1A patent/CN104043058A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1146343A (zh) * | 1995-09-25 | 1997-04-02 | 石建民 | 一种治疗椎间盘病的外敷膏 |
| CN102552705A (zh) * | 2011-11-19 | 2012-07-11 | 李永开 | 一种用于治疗腰椎间盘突出、股骨头坏死的中药胶囊 |
| CN103599379A (zh) * | 2013-12-03 | 2014-02-26 | 杨建勋 | 一种治疗肝肾亏虚型慢性骨髓炎的中药及其制备方法 |
| CN103860815A (zh) * | 2014-03-31 | 2014-06-18 | 张良洁 | 用于治疗自发性气胸的药物组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 周杰: "调补肝肾活血通络法为主治疗腰椎间盘突出症27例", 《广西中医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324332A (zh) * | 2014-11-22 | 2015-02-04 | 王竞鹏 | 一种治疗肝郁气滞型黄褐斑的中药制剂及其制备方法 |
| CN105031502A (zh) * | 2015-09-08 | 2015-11-11 | 王一鸣 | 一种治疗小儿肠炎的药物组合物及其制备方法 |
| TWI804073B (zh) * | 2020-11-27 | 2023-06-01 | 利統股份有限公司 | 用於治療抽筋和痙攣的調配物 |
| US12201667B2 (en) | 2020-11-27 | 2025-01-21 | Lytone Enterprise, Inc. | Formulations for treating cramps and spasms |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105194565A (zh) | 一种用于治疗心脏神经症的中药丸剂及制备方法 | |
| CN103041208B (zh) | 一种治疗妇女更年期综合征的中药制剂及其制备方法 | |
| CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
| CN103990079B (zh) | 用于治疗气滞血瘀型腰肌劳损的药物组合物及其制备方法 | |
| CN104435169A (zh) | 一种治疗骨伤骨折的中药组合物及其制备方法 | |
| CN104127813A (zh) | 一种治疗气血两虚型褥疮的中药组合物及其制备方法 | |
| CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
| CN104998059A (zh) | 祛湿止痹酒 | |
| CN104721582A (zh) | 一种治疗肾虚型月经过少的药物及其制备方法 | |
| CN104815037A (zh) | 一种治疗风湿蕴毒型慢性湿疹的药物及其制备方法 | |
| CN104043058A (zh) | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 | |
| CN105031013A (zh) | 一种治疗腰椎骨质增生的药物及其制备方法 | |
| CN104258300A (zh) | 一种治疗中风后遗症之气虚血瘀型的中药制剂及其制备方法 | |
| CN104095192A (zh) | 一种治疗便秘的米糊 | |
| CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
| CN103520643B (zh) | 一种用于治疗糖尿病白内障的中药制剂及其制备方法 | |
| CN105617268A (zh) | 一种治疗鳞屑角化型脚气的药物 | |
| CN105381441A (zh) | 一种用于防治妊娠水肿的中药胶囊剂及制备方法 | |
| CN104758754A (zh) | 一种治疗肾气虚衰型前列腺增生的药物及制备方法 | |
| CN104352866A (zh) | 一种治疗火毒伤津型烧伤的中药制剂及其制备方法 | |
| CN108714173B (zh) | 一种治疗股骨头坏死湿热瘀阻证的中药组合物、丸剂及其制备方法 | |
| CN104667107A (zh) | 一种治疗暑伤肺胃型小儿暑热症的药物及其制备方法 | |
| CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
| CN104800519A (zh) | 一种治疗冲任失调型乳腺增生的药物及其制备方法 | |
| CN105267895A (zh) | 用于治疗牛产后血瘀型胞衣不下的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |